Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management ...

Hypertension control is critical to prevent stroke. With several clinical trials conducted over the last decade, it seems that the use of an angiotensin-modulating antihypertensive agent conveys ...

A new class of beta blockers designed to activate only when struck by specific wavelengths of light could allow doctors to ...

TheraCryf said on Monday that its lead Ox-1 receptor antagonist programme for addiction had advanced to final toxicology ...

Losartan may help stop the epileptic process in certain patients with hypertension. An observational study that analyzed medical records of 2.26 million patients with hypertension found a roughly 30% ...

Rendering a drug effective or ineffective in a flash at the appropriate location—this is the focus of research in photopharmacology. The goal is to develop drugs that can be switched on and off with ...

Role of the RAAS in the Pathophysiology of Heart Failure ACE inhibitors have no effect on angiotensin II formed by alternate pathways. In contrast, ARBs would be expected to inhibit the biologic ...

Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic ...

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity -- Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome ...

Explore NMDA receptor modulation and its critical role in neuronal development and cognitive functions like learning and ...